FIELD: medicine.
SUBSTANCE: invention describes a method for assessing the effectiveness of Mexidol inclusion in a combination therapy of acute coronary syndrome according to the dynamics of the lipid and phospholipid spectrum of blood serum, wherein established is action of Mexidol on the reduction of the wavy behaviour of the lipid-phospholipid blood serum complexes stabilised at a level sufficient to meet the macronutrient requirements of body and myocardium that is stated to be a positive result of the combination therapy of the patients with acute coronary syndrome.
EFFECT: improving the clinical-functional indices and reducing the wavy behaviour of the lipid and phospholipid blood serum complexes with stabilising their concentration at a permanently high level is considered to be a positive result of the combination therapy of the patients with acute coronary syndrome.
2 ex, 2 dwg
